Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 793505, 12 pages
http://dx.doi.org/10.1155/2013/793505
Review Article

The Involvement of Phospholipases A2 in Asthma and Chronic Obstructive Pulmonary Disease

Department of Immunopathology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, 7/9 Zeligowskiego Street, Building 2, Room 122, 90-752 Lodz, Poland

Received 25 May 2012; Revised 2 January 2013; Accepted 27 February 2013

Academic Editor: Celeste C. Finnerty

Copyright © 2013 Ewa Pniewska and Rafal Pawliczak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Schaloske and E. A. Dennis, “The phospholipase A2 superfamily and its group numbering system,” Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1246–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Masoli, D. Fabian, S. Holt, and R. Beasley, “The global burden of asthma: executive summary of the GINA Dissemination Committee Report,” Allergy, vol. 59, no. 5, pp. 469–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), May 2012, http://www.ginasthma.org.
  4. E. Kitsiouli, G. Nakos, and M. E. Lekka, “Phospholipase A2 subclasses in acute respiratory distress syndrome,” Biochimica et Biophysica Acta, vol. 1792, no. 10, pp. 941–953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Burke and E. A. Dennis, “Phospholipase A2 structure/function, mechanism, and signaling,” Journal of Lipid Research, vol. 50, pp. S237–S242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. The Global Initiative for Chronic Obstructive Lung Disease (GOLD), May 2012, http://www.goldcopd.com/.
  7. H. Nakamura, “Genetics of COPD,” Allergology International, vol. 60, no. 3, pp. 253–258, 2011. View at Google Scholar
  8. E. K. Silverman and F. E. Speizer, “Risk factors for the development of chronic obstructive pulmonary disease,” Medical Clinics of North America, vol. 80, no. 3, pp. 501–522, 1996. View at Google Scholar · View at Scopus
  9. G. Lambeau and M. H. Gelb, “Biochemistry and physiology of mammalian secreted phospholipases A2,” Annual Review of Biochemistry, vol. 77, pp. 495–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Triggiani, G. Giannattasio, C. Calabrese et al., “Lung mast cells are a source of secreted phospholipases A2,” Journal of Allergy and Clinical Immunology, vol. 124, no. 3, pp. 558.e3–565.e3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. N. M. Muñoz, Y. J. Kim, A. Y. Meliton et al., “Human group V phospholipase A2 induces group IVA phospholipase A2-independent cysteinyl leukotriene synthesis in human eosinophils,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 38813–38820, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. C. Seeds, K. K. Peachman, D. L. Bowton, K. L. Sivertson, and F. H. Chilton, “Regulation of arachidonate remodeling enzymes impacts eosinophil survival during allergic asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 3, pp. 358–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Barnes, “Alveolar macrophages as orchestrators of COPD,” Journal of Chronic Obstructive Pulmonary Disease, vol. 1, no. 1, pp. 59–70, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Ichinose, “Differences of inflammatory mechanisms in asthma and COPD,” Allergology International, vol. 58, no. 3, pp. 307–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Giannattasio, Y. Lai, F. Granata et al., “Expression of phospholipases A2 in primary human lung macrophages. Role of cytosolic phospholipase A2-α in arachidonic acid release and platelet activating factor synthesis,” Biochimica et Biophysica Acta, vol. 1791, no. 2, pp. 92–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Degousee, F. Ghomashchi, E. Stefanski et al., “Groups IV, V, and X phospholipases A2s in human neutrophils. Role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis,” Journal of Biological Chemistry, vol. 277, no. 7, pp. 5061–5073, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Granata, V. Nardicchi, S. Loffredo et al., “Secreted phospholipases A2: a proinflammatory connection between macrophages and mast cells in the human lung,” Immunobiology, vol. 214, no. 9-10, pp. 811–821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. I. Yamashita, M. Ogawa, and T. Shirakusa, “Increased expression of membrane-associated phospholipase A2 in the lower respiratory tract of asymptomatic cigarette smokers,” Respiratory Medicine, vol. 90, no. 8, pp. 479–483, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Igarashi, Y. Shibata, K. Yamauchi et al., “Gly80Ser polymorphism of phospholipase A2-IID is associated with cytokine inducibility in A549 cells,” Respiration, vol. 78, no. 3, pp. 312–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. E. Von Allmen, N. Schmitz, M. Bauer et al., “Secretory phospholipase A2-IID is an effector molecule of CD4+ CD25+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 28, pp. 11673–11678, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. P. Nana, J. D. Lee, S. Sotto-Santiago et al., “Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 7, pp. 676–685, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Pawliczak, “The role of radical oxygen species in airway inflammation,” Polski Merkuriusz Lekarski, vol. 14, no. 84, pp. 493–496, 2003. View at Google Scholar · View at Scopus
  23. A. Y. Meliton, N. M. Muñoz, A. Lambertino et al., “Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B4 and TNF-α in human neutrophils,” European Respiratory Journal, vol. 28, no. 5, pp. 920–928, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Tanaseanu, S. Tudor, I. Tamsulea, D. Marta, G. Manea, and E. Moldoveanu, “Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus,” European Journal of Medical Research, vol. 12, no. 4, pp. 145–151, 2007. View at Google Scholar · View at Scopus
  25. Y. J. Kim, K. P. Kim, S. K. Han et al., “Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 36479–36488, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. D. L. Bowton, A. A. Dmitrienko, E. Israel, B. G. Zeiher, and G. D. Sides, “Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma,” Journal of Asthma, vol. 42, no. 1, pp. 65–71, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Dennis, “Phospholipase A2 in eicosanoid generation,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, part 2, pp. S32–S35, 2000. View at Google Scholar
  28. T. J. Shuttleworth, “Arachidonic acid activates the noncapacitative entry of Ca2+ during [Ca2+]i oscillations,” Journal of Biological Chemistry, vol. 271, no. 36, pp. 21720–21725, 1996. View at Google Scholar · View at Scopus
  29. M. N. Graber, A. Alfonso, and D. L. Gill, “Ca2+ pools and cell growth: arachidonic acid induces recovery of cells growth-arrested by Ca2+ pool depletion,” Journal of Biological Chemistry, vol. 271, no. 2, pp. 883–888, 1996. View at Google Scholar · View at Scopus
  30. C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Uddin and B. D. Levy, “Resolvins: natural agonists for resolution of pulmonary inflammation,” Progress in Lipid Research, vol. 50, no. 1, pp. 75–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Planagumà, S. Kazani, G. Marigowda et al., “Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 6, pp. 574–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. D. Levy, C. Bonnans, E. S. Silverman, L. J. Palmer, C. Marigowda, and E. Israel, “Diminished lipoxin biosynthesis in severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 7, pp. 824–830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. D. H. Adler, J. D. Cogan, J. A. Phillips et al., “Inherited human cPLA2α deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction,” Journal of Clinical Investigation, vol. 118, no. 6, pp. 2121–2131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. K. A. Reed, D. E. Tucker, A. Aloulou et al., “Functional characterization of mutations in inherited human cPLA2 deficiency,” Biochemistry, vol. 50, no. 10, pp. 1731–1738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Sokolowska, M. Borowiec, A. Ptasinska et al., “85-kDa cytosolic phospholipase A2 group IVα gene promoter polymorphisms in patients with severe asthma: a gene expression and case-control study,” Clinical and Experimental Immunology, vol. 150, no. 1, pp. 124–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Sokolowska, J. Stefanska, K. Wodz-Naskiewicz, and R. Pawliczak, “Cytosolic phospholipase A2 group IVA influence on GM-CSF expression in human lung cells: a pilot study,” Medical Science Monitor, vol. 16, no. 9, pp. BR300–BR306, 2010. View at Google Scholar · View at Scopus
  38. K. A. Whalen, H. Legault, C. Hang et al., “In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2α overcomes the asthma-associated response,” Clinical and Experimental Allergy, vol. 38, no. 10, pp. 1590–1605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. T. S. Hallstrand, E. Y. Chi, A. G. Singer, M. H. Gelb, and W. R. Henderson, “Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness,” American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 11, pp. 1072–1078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Asai, T. Hirabayashi, T. Houjou, N. Uozumi, R. Taguchi, and T. Shimizu, “Human group IVC phospholipase A2 (cPLA2γ): roles in the membrane remodeling and activation induced by oxidative stress,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8809–8814, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. D. J. Mancuso, D. R. Abendschein, C. M. Jenkins et al., “Cardiac ischemia activates calcium-independent phospholipase A2β, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22231–22236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. G. M. Gauvreau, R. M. Watson, and P. M. O'Byrne, “Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 1, pp. 31–36, 1999. View at Google Scholar · View at Scopus
  43. K. F. Chung, “Evaluation of selective prostaglandin E2 (PGE2) receptor agonists as therapeutic agents for the treatment of asthma,” Science's STKE, vol. 2005, no. 303, p. pe47, 2005. View at Google Scholar · View at Scopus
  44. B. Sastre and V. del Pozo, “Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis,” Mediators of Inflammation, vol. 2012, Article ID 645383, 9 pages, 2012. View at Publisher · View at Google Scholar
  45. R. P. Phipps, S. H. Stein, and R. L. Roper, “A new view of prostaglandin E regulation of the immune response,” Immunology Today, vol. 12, no. 10, pp. 349–352, 1991. View at Google Scholar · View at Scopus
  46. S. Yedgar, M. Krimsky, Y. Cohen, and R. J. Flower, “Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword?” Trends in Pharmacological Sciences, vol. 28, no. 9, pp. 459–464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. F. H. Chilton, F. J. Averill, W. C. Hubbard, A. N. Fonteh, M. Triggiani, and M. C. Liu, “Antigen-induced generation of lyso-phospholipids in human airways,” Journal of Experimental Medicine, vol. 183, no. 5, pp. 2235–2245, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. D. L. Bowton, M. C. Seeds, M. B. Fasano, B. Goldsmith, and D. A. Bass, “Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 2, pp. 421–425, 1997. View at Google Scholar · View at Scopus
  49. W. R. Henderson, E. Y. Chi, J. G. Bollinger et al., “Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model,” Journal of Experimental Medicine, vol. 204, no. 4, pp. 865–877, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. T. S. Hallstrand, Y. Lai, Z. Ni et al., “Relationship between levels of secreted phospholipase A2 groups IIA and X in the airways and asthma severity,” Clinical and Experimental Allergy, vol. 41, no. 6, pp. 801–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Lai, R. C. Oslund, J. G. Bollinger et al., “Eosinophil cysteinyl leukotriene synthesis mediated by exogenous secreted phospholipase A2 group X,” Journal of Biological Chemistry, vol. 285, no. 53, pp. 41491–41500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Murakami, Y. Taketomi, H. Sato, and K. Yamamoto, “Secreted phospholipase A2 revisited,” Journal of Biochemistry, vol. 150, no. 3, pp. 233–255, 2011. View at Google Scholar
  53. M. Murakami, Y. Taketomi, Y. Miki, H. Sato, T. Hirabayashi, and K. Yamamoto, “Recent progress in phospholipase A2 research: from cells to animals to humans,” Progress in Lipid Research, vol. 50, no. 2, pp. 152–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Kudo and M. Murakami, “Phospholipase A2 enzymes,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 3–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. H. K. Tay and A. J. Melendez, “FcγRI-triggered generation of arachidonic acid and eicosanoids requires iPLA2 but not cPLA2 in human monocytic cells,” Journal of Biological Chemistry, vol. 279, no. 21, pp. 22505–22513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Murakami, S. Masuda, K. Ueda-Semmyo et al., “Group VIB Ca2+-independent phospholipase A2γ promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2,” Journal of Biological Chemistry, vol. 280, no. 14, pp. 14028–14041, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. T. M. McIntyre, S. M. Prescott, and D. M. Stafforini, “The emerging roles of PAF acetylhydrolase,” Journal of Lipid Research, vol. 50, pp. S255–S259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. D. M. Stafforini, T. Numao, A. Tsodikov et al., “Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma,” Journal of Clinical Investigation, vol. 103, no. 7, pp. 989–997, 1999. View at Google Scholar · View at Scopus
  59. S. Kruse, X. Q. Mao, A. Heinzmann et al., “The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activities and are associated with atopy and asthma,” American Journal of Human Genetics, vol. 66, no. 5, pp. 1522–1530, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. W. R. Henderson, J. Lu, K. M. Poole, G. N. Dietsch, and E. Y. Chi, “Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model,” Journal of Immunology, vol. 164, no. 6, pp. 3360–3367, 2000. View at Google Scholar · View at Scopus
  61. N. R. Henig, M. L. Aitken, M. C. Liu, A. S. Yu, and W. R. Henderson, “Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 2, part 1, pp. 523–527, 2000. View at Google Scholar · View at Scopus
  62. R. Rivera and J. Chun, “Biological effects of lysophospholipids,” Reviews of Physiology, Biochemistry and Pharmacology, vol. 160, pp. 25–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. J. A. Urbina, “Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 100, supplement 1, pp. S9–S16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. B. P. Hurley and B. A. McCormick, “Multiple roles of phospholipase A2 during lung infection and inflammation,” Infection and Immunity, vol. 76, no. 6, pp. 2259–2272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. R. D. Hite, M. C. Seeds, R. B. Jacinto, B. L. Grier, B. M. Waite, and D. A. Bass, “Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis,” Biochimica et Biophysica Acta, vol. 1720, no. 1-2, pp. 14–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. M. A. Kwatia, C. B. Doyle, W. Cho, G. Enhorning, and S. J. Ackerman, “Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis,” Journal of Allergy and Clinical Immunology, vol. 119, no. 4, pp. 838–847, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. J. Ackerman, M. A. Kwatia, C. B. Doyle, and G. Enhorning, “Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma,” Chest, vol. 123, no. 3, p. 355S, 2003. View at Google Scholar · View at Scopus
  68. G. Enhorning, “Surfactant in airway disease,” Chest, vol. 133, no. 4, pp. 975–980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Hiraoka, A. Abe, Y. Lu et al., “Lysosomal phospholipase A2 and phospholipidosis,” Molecular and Cellular Biology, vol. 26, no. 16, pp. 6139–6148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. R. S. Koduri, J. O. Grönroos, V. J. O. Laine et al., “Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A2,” Journal of Biological Chemistry, vol. 277, no. 8, pp. 5849–5857, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Rouault, C. Le Calvez, E. Boilard et al., “Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor,” Biochemistry, vol. 46, no. 6, pp. 1647–1662, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Triggiani, F. Granata, A. Frattini, and G. Marone, “Activation of human inflammatory cells by secreted phospholipases A2,” Biochimica et Biophysica Acta, vol. 1761, no. 11, pp. 1289–1300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Ancian, G. Lambeau, and M. Lazdunski, “Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2,” Biochemistry, vol. 34, no. 40, pp. 13146–13151, 1995. View at Google Scholar · View at Scopus
  74. F. Granata, R. I. Staiano, S. Loffredo et al., “The role of mast cell-derived secreted phospholipases A2 in respiratory allergy,” Biochimie, vol. 92, no. 6, pp. 588–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Triggiani, F. Granata, A. Oriente et al., “Secretory phospholipases A2 induce β-glucuronidase release and IL-6 production from human lung macrophages,” Journal of Immunology, vol. 164, no. 9, pp. 4908–4915, 2000. View at Google Scholar · View at Scopus
  76. C. C. Silliman, E. E. Moore, G. Zallen et al., “Presence of the M-type sPLA2 receptor on neutrophils and its role in elastase release and adhesion,” American Journal of Physiology, vol. 283, no. 4, pp. C1102–C1113, 2002. View at Google Scholar · View at Scopus
  77. A. Gambero, E. C. T. Landucci, M. H. Toyama et al., “Human neutrophil migration in vitro induced by secretory phospholipases A2: a role for cell surface glycosaminoglycans,” Biochemical Pharmacology, vol. 63, no. 1, pp. 65–72, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Triggiani, F. Granata, B. Balestrieri et al., “Secretory phospholipases A2 activate selective functions in human eosinophils,” Journal of Immunology, vol. 170, no. 6, pp. 3279–3288, 2003. View at Google Scholar · View at Scopus
  79. Z. Ni, N. M. Okeley, B. P. Smart, and M. H. Gelb, “Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells,” Journal of Biological Chemistry, vol. 281, no. 24, pp. 16245–16255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. M. A. Balboa, R. Pérez, and J. Balsinde, “Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid,” Journal of Immunology, vol. 171, no. 2, pp. 989–994, 2003. View at Google Scholar · View at Scopus
  81. S. Offer, S. Yedgar, O. Schwob et al., “Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats,” American Journal of Physiology, vol. 288, no. 3, pp. L523–L529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. A. N. Fonteh, G. I. Atsumi, T. LaPorte, and F. H. Chilton, “Secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2 in murine bone marrow-derived mast cells,” Journal of Immunology, vol. 165, no. 5, pp. 2773–2782, 2000. View at Google Scholar · View at Scopus
  83. Y. J. Jiang, B. Lu, P. C. Choy, and G. M. Hatch, “Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TNFα, LPS and M-CSF in human monocytes and macrophages,” Molecular and Cellular Biochemistry, vol. 246, no. 1-2, pp. 31–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. P. Dieter, A. Kolada, S. Kamionka, A. Schadow, and M. Kaszkin, “Lipopolysaccharide-induced release of arachidonic acid and prostaglandins in liver macrophages: regulation by Group IV cytosolic phospholipase A2, but not by Group V and Group IIA secretory phospholipase A2,” Cellular Signalling, vol. 14, no. 3, pp. 199–204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Y. Qi and J. H. Shelhamer, “Toll-like receptor 4 signaling regulates cytosolic phospholipase A2 activation and lipid generation in lipopolysaccharide-stimulated macrophages,” Journal of Biological Chemistry, vol. 280, no. 47, pp. 38969–38975, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. W. Tian, G. T. Wijewickrama, J. H. Kim et al., “Mechanism of regulation of group IVA phospholipase A2 activity by Ser727 phosphorylation,” Journal of Biological Chemistry, vol. 283, no. 7, pp. 3960–3971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. X. Zhou, W. Yang, and J. Li, “Ca2+- and protein kinase C-dependent signaling pathway for nuclear factor-κB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-α production in lipopolysaccharide-stimulated rat peritoneal macrophages,” Journal of Biological Chemistry, vol. 281, no. 42, pp. 31337–31347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. M. J. Coffey, S. M. Phare, and M. Peters-Golden, “Induction of inducible nitric oxide synthase by lipopolysaccharide/ interferon gamma and sepsis down-regulates 5-lipoxygenase metabolism in murine alveolar macrophages,” Experimental Lung Research, vol. 30, no. 7, pp. 615–633, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. U. T. Shankavaram, D. L. DeWitt, and L. M. Wahl, “Lipopolysaccharide induction of monocyte matrix metalloproteinases is regulated by the tyrosine phosphorylation of cytosolic phospholipase A2,” Journal of Leukocyte Biology, vol. 64, no. 2, pp. 221–227, 1998. View at Google Scholar · View at Scopus
  90. U. A. Kessen, R. H. Schaloske, D. L. Stephens, K. K. Lucas, and E. A. Dennis, “PGE2 release is independent of upregulation of Group V phospholipase A2 during long-term stimulation of P388D1 cells with LPS,” Journal of Lipid Research, vol. 46, no. 11, pp. 2488–2496, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Shridas, W. M. Bailey, K. R. Talbott, R. C. Oslund, M. H. Gelb, and N. R. Webb, “Group X secretory phospholipase A2 enhances TLR4 signaling in macrophages,” Journal of Immunology, vol. 187, no. 1, pp. 482–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Hamaguchi, H. Kuwata, K. Yoshihara et al., “Induction of distinct sets of secretory phospholipase A2 in rodents during inflammation,” Biochimica et Biophysica Acta, vol. 1635, no. 1, pp. 37–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. W. R. Hendersen, R. C. Oslund, J. G. Bollinger, X. Ye, Y. T. Tien, J. Xue et al., “Blockade of human group X secreted phospholipase A2-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective group X secreted phospholipase A2 inhibitor,” The Journal of Biological Chemistry. In press.
  94. N. M. Muñoz, A. Y. Meliton, L. N. Meliton, S. M. Dudek, and A. R. Leff, “Secretory group V phospholipase A2 regulates acute lung injury and neutrophilic inflammation caused by LPS in mice,” American Journal of Physiology, vol. 296, no. 6, pp. L879–L887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. N. M. Muñoz, A. Y. Meliton, J. P. Arm, J. V. Bonventre, W. Cho, and A. R. Leff, “Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice,” The Journal of Immunology, vol. 179, no. 7, pp. 4800–4807, 2007. View at Google Scholar
  96. R. Malaviya, J. Ansell, L. Hall et al., “Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice,” European Journal of Pharmacology, vol. 539, no. 3, pp. 195–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. J. C. McKew, K. L. Lee, M. W. H. Shen et al., “Indole cytosolic phospholipase A2α inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4- dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl} benzoic acid, efipladib,” Journal of Medicinal Chemistry, vol. 51, no. 12, pp. 3388–3413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. K. L. Lee, M. A. Foley, L. Chen et al., “Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α,” Journal of Medicinal Chemistry, vol. 50, no. 6, pp. 1380–1400, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. C. A. Hewson, S. Patel, L. Calzetta et al., “Preclinical evaluation of an inhibitorof cytosolic phospholipase A2α for the treatment of asthma,” Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 3, pp. 656–665, 2012. View at Google Scholar
  100. F. Hirata, E. Schiffmann, and K. Venkatasubramanian, “A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 5, pp. 2533–2536, 1980. View at Google Scholar · View at Scopus
  101. R. De Caterina, R. Sicari, D. Giannessi et al., “Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids,” Journal of Applied Physiology, vol. 75, no. 6, pp. 2368–2375, 1993. View at Google Scholar · View at Scopus
  102. X. Huang, R. Pawliczak, X. L. Yao et al., “Characterization of the human p11 promoter sequence,” Gene, vol. 310, no. 1-2, pp. 133–142, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. X. L. Huang, R. Pawliczak, X. L. Yao et al., “Interferon-γ induces p11 gene and protein expression in human epithelial cells through interferon-γ-activated sequences in the p11 promoter,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9298–9308, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. X. L. Yao, M. J. Cowan, M. T. Gladwin, M. M. Lawrence, C. W. Angus, and J. H. Shelhamer, “Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17202–17208, 1999. View at Publisher · View at Google Scholar · View at Scopus
  105. L. H. K. Lim and S. Pervaiz, “Annexin 1: the new face of an old molecule,” The FASEB Journal, vol. 21, no. 4, pp. 968–975, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Nakano, O. Ohara, H. Teraoka, and H. Arita, “Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression,” Journal of Biological Chemistry, vol. 265, no. 21, pp. 12745–12748, 1990. View at Google Scholar · View at Scopus
  107. U. R. Juergens, F. Jäger, W. Darlath, M. Stöber, H. Vetter, and A. Gillissen, “Comparison of in vitro-activity of common used topical glucocorticoids on cytokine- and phospholipase inhibition,” European Journal of Medical Research, vol. 9, no. 8, pp. 383–390, 2004. View at Google Scholar · View at Scopus
  108. J. H. Kwon, J. H. Lee, K. S. Kim, Y. W. Chung, and I. Y. Kim, “Regulation of cytosolic phospholipase A2 phosphorylation by proteolytic cleavage of annexin A1 in activated mast cells,” The Journal of Immunology, vol. 188, no. 11, pp. 5665–5673, 2012. View at Google Scholar
  109. C. Guo, J. Li, L. Myatt, X. Zhu, and K. Sun, “Induction of Gαs contributes to the paradoxical stimulation of cytosolic phospholipase A2α expression by cortisol in human amnion fibroblasts,” Molecular Endocrinology, vol. 24, no. 5, pp. 1052–1061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Guo, Z. Yang, W. Li, P. Zhu, L. Myatt, and K. Sun, “Paradox of glucocorticoid-induced cytosolic phospholipase A2 group IVA messenger RNA expression involves glucocorticoid receptor binding to the promoter in human amnion fibroblasts,” Biology of Reproduction, vol. 78, no. 1, pp. 193–197, 2008. View at Publisher · View at Google Scholar · View at Scopus